Rznomics Company Description

Rznomics Inc. develops RNA based gene therapies for cancers and intractable diseases.

Its development stage product candidates include RZ-001_immune therapy combination product, which is in Phase 1b/2a stage for treating Hepatocellular carcinoma; RZ-001 (GBM) that is in Phase 1/2a stage for Glioblastoma; RZ-003, which is in discovery stage for Alzheimer; RZ-004, a pre-clinical product for Retinitis Pigmentosa; and RZ-005, a discovery stage product to treat Rett Syndrome.

Rznomics Inc. was incorporated in 2017 and is headquartered in Seongnam-si, South Korea.

Rznomics Inc.

Country	South Korea
Founded	2017
Industry	Biological Products, Except Diagnostic Substances
CEO	Lee Seong-wook

Contact Details

Address: #801 Innovalley Bldg. C Seongnam-si, 13486 South Korea
Phone	82 3 1706 8730
Website	rznomics.com

Stock Details

Ticker Symbol	476830
Exchange	KOSDAQ
Reporting Currency	KRW
SIC Code	2836

Key Executives

Name	Position
Lee Seong-wook	Chief Executive Officer
Rim Jong-Sun	Chief Financial Officer